This study is looking at how well Duobrii, a topical medication, works when added to your current biologic therapy for psoriasis. You might be able to join if you are an adult with chronic plaque-type psoriasis affecting 2% to 10% of your body, and you've been on a biologic therapy for at least 24 weeks. The study wants to see if Duobrii improves the amount of body surface area (BSA) affected by psoriasis after 8 weeks. The current status of this study is unclear, and it plans to enroll 25 participants.

Study design

This is a single-center pilot study with 25 participants. The phase of the study is not specified.

What's involved

You would apply Duobrii daily for 4 weeks, then every other day for another 4 weeks. The study assesses your body surface area improvement at 8 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for improvement is measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.